1-4 of 4
Barinder Kang
Close
Sort by
Journal Articles

The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients

Frank Giles, MD MB, FRCPI, FRCPath, Sarina A. Piha-Paul, MD, Alexander I. Spira, PhD MD FACP, Fadi Braiteh, MD CPI, Julio Antonio Peguero, MD, Daniel L. Spitz, MD FACP, James A. Knost, MD, Lee Schwartzberg, MD FACP, Steven Stein, MD, August J. Salvado, MD, Claudia Lebedinsky, MD, Barinder Kang, PhD, Eric Slosberg, PhD
Journal: Blood
Blood (2014) 124 (21): 4818.
https://doi.org/10.1182/blood.V124.21.4818.4818
Published: 2014
Journal Articles

Initial Liver Iron Predicts Cardiac Chelation Efficacy of Deferasirox (Exjade®) Monotherapy in Chronically Transfused β-Thalassemia (β-Thal) Patients: 18- and 24-Month Data.

John C. Wood, Alexis A. Thompson, Carole Paley, Tara Glynos, Barinder Kang, Patricia J. Giardina, Paul R. Harmatz, Thomas Coates
Journal: Blood
Blood (2009) 114 (22): 4069.
https://doi.org/10.1182/blood.V114.22.4069.4069
Published: 2009
Journal Articles

Deferasirox (Exjade ® ) Monotherapy Significantly Reduces Cardiac Iron Burden in Chronically Transfused β-Thalassemia Patients: An MRI T2* Study

John C Wood, Alexis A. Thompson, MD, MPH, Carole Paley, Barinder Kang, Patricia Giardina, Paul Harmatz, M.D., Jodi Virkus, Thomas D Coates
Journal: Blood
Blood (2008) 112 (11): 3882.
https://doi.org/10.1182/blood.V112.11.3882.3882
Published: 2008
Journal Articles

Liver Iron Concentration Measurements Using MRI R2 in MDS Patients in a Deferasirox (Exjade®, ICL670) Phase II Study.

Peter L. Greenberg, Charles A. Schiffer, Charles Asa Koller, Barinder Kang, Jodie Decker, Carole Paley
Journal: Blood
Blood (2006) 108 (11): 4846.
https://doi.org/10.1182/blood.V108.11.4846.4846
Published: 2006